Immunologic effects of AS101 in the treatment of cancer patients

A. Shani, T. Tichler, R. Catane, M. Gurwith, L. A. Rozenszajn, A. Gezin, E. Levi, M. Schlesinger, Y. Kalechman, H. Michlin, F. Shalit, E. Engelsman, H. Farbstein, M. Farbstein, M. Albeck, B. Sredni

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

AS101 [ammonium trichloro(O,O'-dioxyethylene)tellurate] is a new immunomodulator previously shown to stimulate the production of different cytokines in vitro and in vivo. We report here our results of a phase I clinical trial conducted on 47 cancer patients with advanced malignancies. AS101 was administered intravenously at escalating doses from 1 to 10 mg/m2, twice or thrice a week. The maximal tolerated dose has not yet been determined. However, significant immunologic responses were noted at dose levels of 1-3 mg/m2 administered three times a week. At these doses statistically significant rises in γ-interferon, natural killer cell activity, tumor necrosis factor and interleukin-2 (IL-2) levels as well as the expression of IL-2 receptors were noted. In most of the immunologic parameters the maximal response was seen at 3 mg/m2. Throughout the study toxicity was minimal. In view of these results phase II studies are currently being initiated.

Original languageEnglish
Pages (from-to)182-190
Number of pages9
JournalNatural Immunity and Cell Growth Regulation
Volume9
Issue number3
StatePublished - 1990
Externally publishedYes

Fingerprint

Dive into the research topics of 'Immunologic effects of AS101 in the treatment of cancer patients'. Together they form a unique fingerprint.

Cite this